New COVID-19 Vaccine Formulations

IMPORTANT: Bivalent Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines are no longer authorized for use as of Tuesday, September 12, 2023:

- Remove any bivalent mRNA COVID-19 vaccines immediately from your inventory and dispose of them following your practice protocols and report the discarded vaccine as ‘wasted’ in myCAvax.
- Unauthorized doses administered after September 12, 2023 must be reported in the Vaccine Adverse Event Reporting System (VAERS).

CDC recommends everyone 6 months and older receive an updated mRNA COVID-19 vaccine containing the 2023-2024 formulation. The newly approved and authorized formulations of Pfizer and Moderna COVID-19 vaccines target circulating variants that are currently responsible for the most infections and hospitalizations in the United States. Updated vaccines include a monovalent (single) component that corresponds to the Omicron variant XBB.1.5.

- The 2023-2024 formulations of the Pfizer and Moderna COVID-19 vaccines have been authorized under emergency use for persons 6 months through 11 years.
  - Moderna EUA
  - Pfizer-BioNTech EUA
- The 2023–24 COVID-19 Spikevax mRNA vaccine from Moderna and Comirnaty mRNA vaccine from Pfizer have been approved for a single dose for persons 12 years of age and older.
- The 2023-2024 Novavax vaccine is currently under review by the FDA. The original formulation of Novavax vaccine may still be administered until further notice.

Who should receive the updated vaccine, and when?

Vaccine recommendations are based on age, which vaccines were received previously, and time since last dose.

- **Everyone aged 5 years and older** should get 1 dose of the updated Pfizer-BioNTech or Moderna COVID-19 vaccine to protect against serious illness from COVID-19.
- **People who are moderately or severely immunocompromised** may get additional doses of updated COVID-19 vaccine.
  - Not previously vaccinated: should receive a 3-dose series of updated (2023-2024 Formula) Moderna or updated (2023-2024 Formula) Pfizer-BioNTech COVID-19 vaccine
  - Previously received mRNA doses: need 1 or 2 doses of updated (2023-2024 Formula) Moderna or updated (2023-2024 Formula) Pfizer-BioNTech COVID-19 vaccine, depending on the number of prior doses
- **Children aged 6 months–4 years** need multiple doses of COVID-19 vaccines to be up to date, including at least 1 dose of updated COVID-19 vaccine.
  - Not previously vaccinated: should receive either 2 doses of updated (2023-2024 Formula) Moderna, or 3 doses of updated (2023-2024 Formula) Pfizer-BioNTech COVID-19 vaccine
  - Previously received some mRNA doses: need 1 or 2 doses of updated (2023-2024 Formula) Moderna or updated (2023-2024 Formula) Pfizer-BioNTech COVID-19 vaccine, depending on the number of prior doses
  - Previously up to date: 1 dose of the updated Pfizer-BioNTech or Moderna COVID-19 vaccines
    - For those ages 6 months–4 years, only a homologous dose may be administered.
    - For those ages 5 years and older, a dose from either manufacturer may be administered.
The original Novavax COVID-19 vaccine remains authorized for use as a 2-dose primary series for individuals 12 years and older. Authorizations or approvals for 2023–2024 Novavax COVID-19 vaccine will be determined by FDA with CDC recommendations to follow. At this time, the original Novavax COVID-19 vaccine can be given as booster dose in limited situations to individuals who are:

- Aged 18 years and older who previously completed primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine
- Have not received any previous booster dose(s)
- Are unwilling or unable (i.e., mRNA vaccine contraindicated or not available) to receive an updated mRNA vaccine and would otherwise not receive vaccine

### Placing COVID-19 Vaccine Orders

- VFC providers may order vaccines through the myVFCvaccines website.
- Providers selected to participate in the Bridge Access Program (BAP) will order through their myCAvax account.
- Providers who wish to purchase the updated COVID-19 vaccine, may order through traditional procurement pathways:
  - **Spikevax**: Providers can order through McKesson, Cardinal, and AmeriSource Bergen distributors or directly on the Moderna website or by calling 1-866-MODERNA (1-866-663-3762).
  - **Comirnaty**: Providers may work with wholesalers prior to and post launch of approved products or directly with Pfizer for minimum quantities on the Pfizer website or by calling (1-800-666-7248).
  - **Novavax**: For more information on product purchasing, email Novavax CA regional Business Director Nidal Naser at nnaser@novavax.com.

### Scheduling Vaccine Appointments Through My Turn

The My Turn system gives providers an all-in-one application for vaccine eligibility, public appointment scheduling, walk-in appointments, dose administration, and reporting for vaccine clinics. My Turn currently supports appointments for COVID-19, Flu, and Mpox vaccinations, with broader vaccine support coming soon.

- DPH encourages providers to continue utilizing My Turn to schedule vaccine appointments.
- Providers who are not scheduling patients through My Turn can enroll by contacting My Turn directly.

### Co-Administering Other Recommended Vaccines

Co-administration of any combination of Flu, COVID-19, and RSV vaccines is encouraged for eligible patients. For details, visit Simultaneous administration other COVID-19 vaccines with other vaccines.

### REQUIRED: Document all vaccines in CAIR2

**CAIR2** (California Immunization Registry): Reporting of all doses administered is required for all healthcare providers in California, **effective Jan 1, 2023**.

- Enroll in CAIR2 to report vaccines administered at your site. Once enrolled, visit the log in page for CAIR2 and report all administered doses, including Flu and RSV, to CAIR within 24 hours.